Atea Pharmaceuticals to Present New Data Supporting Combination of Bemnifosbuvir and Ruzasvir as Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025

Core Insights - Atea Pharmaceuticals announced new data supporting the combination regimen of bemnifosbuvir and ruzasvir as a potential best-in-class treatment for hepatitis C (HCV) at The Liver Meeting 2025 [1][2] - The company is advancing its global Phase 3 program, with patient enrollment ongoing, and is optimistic about reshaping the standard of care for HCV [2][8] Clinical Data and Presentations - Three abstracts will be presented at The Liver Meeting 2025, including results from a Phase 2 study and a Phase 1 study on the fixed-dose combination [1][2] - The Phase 2 study showed a 98% sustained virologic response (SVR12) in the treatment-adherent population and a 95% SVR12 in the efficacy evaluable population [4][5] - The combination regimen demonstrated high relative bioavailability and can be dosed without regard to food [4][5] Ongoing Trials - Atea's Phase 3 development program includes two trials: C-BEYOND in the US and Canada, and C-FORWARD outside North America, each enrolling approximately 880 treatment-naïve patients [9][10] - The primary endpoint for these trials is HCV RNA below the lower limit of quantitation at 24 weeks, ensuring consistent measurement across all patients [10] Market Context and Challenges - HCV remains a significant global healthcare issue, with approximately 50 million people chronically infected worldwide and an estimated 240,000 deaths annually [11] - In the US, between 2.4 and 4 million people are estimated to have HCV, with new infections outpacing treatment rates [11] Drug Profile - Bemnifosbuvir has shown to be approximately 10-fold more active than sofosbuvir against various HCV genotypes and has a favorable safety profile [12] - Ruzasvir has demonstrated potent antiviral activity and a favorable safety profile in clinical studies [12] Upcoming Events - Atea will host a virtual key opinion leader (KOL) investor event on November 13, 2025, to discuss the HCV commercial market opportunity and ongoing clinical development [6][8]